A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

• Status: Completed
• Trial end date: 1969-12-31

Summary

To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.

• Phase: Phase 2

Details

• Lead Sponsor: Ionis Pharmaceuticals, Inc.
• Treatments: Fomivirsen; Ganciclovir; Ganciclovir triphosphate